MedTrace Logo

A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss

NCT01900041 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2013-12-12

No results posted yet for this study

Summary

Pantovigar - a high effective product designed primarily for the treatment of diffuse hair loss in women as well as for the treatment of damaged hair, in the combined therapy can be successfully applied in other types of alopecia.

The purpose of this study is to evaluate efficacy and tolerability of combination therapy Pantovigar plus 2% minoxidil vs 2% minoxidil. To collect tolerability data for combined treatment Pantovigar plus 2% Minoxidil course therapy.

Conditions

  • Female Pattern Hair Loss
  • Androgenetic Alopecia (AGA)
  • Ludwig Type 1
  • Ludwig Type 2

Interventions

DRUG

Pantovigar

1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.

DRUG

Minoxidil 2% only

1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.

Sponsors & Collaborators

  • LLC Merz Pharma, Russia

    collaborator UNKNOWN

  • Merz Pharmaceuticals GmbH

    lead INDUSTRY

Principal Investigators

  • Medical Expert · LLC Merz Pharma, Russia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-05-31
Completion
2013-07-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01900041 on ClinicalTrials.gov